State-of-the-art resources and expertise
Our cutting-edge equipment and team of brilliant scientists are dedicated to your project's success. Our approach is grounded in data, providing reliable insights and fostering collaborations that drive meaningful progress toward advancing treatments and cures for blindness.
Optimized study design for reliable outcomes
Let us help you design a study and ask the best questions that are optimized for reliable outcomes. Our ability to help researchers overcome resource challenges sets us apart, ensuring you have the support needed to bring projects to fruition.
Bridging the gap between science and eye banking
We have an excellent understanding of the intersection of basic/translational science and eye banking, bridging the gap between your expectations and the end results. Our expertise ensures your research is grounded in real-world applications and practical considerations.
Comprehensive eye and vision research solutions
- State-of-the-art facilities and equipment
- Dedicated team of expert scientists
- Study design and optimization
- Access to human eye tissue and biofluids
- Data analysis and insights
- Collaboration and partnership opportunities
Key academic and research partnerships
By partnering with Eversight, you join a powerful cohort focused on advancing science to make vision a reality for more people worldwide—for generations to come. Our collaborative approach brings together academia, biotech and pharma to drive groundbreaking discoveries.
Our current partners
Projects
Emmecell
Challenge
Currently, the only way to restore sight to patients with advanced cases of corneal edema due to endothelial cell dysfunction is by cornea transplant. Emmecell’s minimally invasive cell therapy injects healthy corneal endothelial cells obtained from donor corneas into the eye to repopulate the patient’s diseased cornea with functioning endothelial cells, potentially eliminating the need for transplantation.
Idea
One donor cornea can restore vision to one recipient eye through transplantation. However, corneal endothelial cells from a single donor tissue could be amplified using Emmecell’s technology to restore vision for hundreds of patients via injectable cell therapy.
To date, cell therapies that replace or enhance damaged tissue often have been limited by the inability to localize treatment to the site of injury or disease. Using a proprietary Magnetic Cell Delivery (MCD) nanoparticle platform, Emmecell solves the therapeutic challenges of delivery, retention and integration of healthy donor cells.
Goal
Eversight is partnering with Emmecell because alternative cell therapies made possible by their technology have the potential to transform more lives in developing countries without the need for local eye banking infrastructure or imported donor tissue.
Phoenix Nest
Challenge
Research on the retinal manifestations of Sanfilippo syndrome—also called mucopolysaccharidosis (MPS) IIIC disorder—aims to help physicians better diagnose children who are in early stages of the disease, before behavioral and physical symptoms manifest. This terminal disorder is caused by a single genetic defect that leads to the progressive degeneration of the central nervous system.
Idea
Eversight is partnering with Phoenix Nest to better understand how MPS IIIC manifests in the retina, the nerve layer lining the back of the eye that senses light and sends electrical impulses through the optic nerve to the brain that enables sight.
Goal
Findings aim to help bring researchers one step closer to better understanding the physiological mechanisms of MPS IIIC and, one day, find a treatment or cure.
HYGELIX
Challenge
Transplants can restore sight to millions globally, but the procedure can be difficult to perform due to lack of training and the nature of the donor tissue needed. This results in surgeon reluctance to perform the procedure, despite the significant benefits of this technique, including faster recovery times, shorter procedures and better patient outcomes.
Idea
To address the global need for corneas, Eversight is working with partners in Australia to develop a product called HYGELIX, an ultrathin hydrogel scaffold that attaches to donor corneal tissue. HYGELIX supports and protects the donor tissue, minimizes tissue scrolling and makes the positioning of the tissue during surgery easier.
Goal
If successful, HYGELIX could:
- Increase the uptake and accessibility of EK transplant surgery.
- Improve patient visual outcomes and prevent donor rejection and regraft.
- Increase global access to corneal tissue and reduce tissue waste.
- Reduce avoidable corneal blindness and increase access to surgical services.
- Assist in the development of a bioengineered cornea.
Connect with Eversight R&D
Contact Eversight today to discuss how our comprehensive resources and expertise can support your next groundbreaking eye and vision research project.
Contact us
